ATE211762T1 - Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) - Google Patents
Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)Info
- Publication number
- ATE211762T1 ATE211762T1 AT94916170T AT94916170T ATE211762T1 AT E211762 T1 ATE211762 T1 AT E211762T1 AT 94916170 T AT94916170 T AT 94916170T AT 94916170 T AT94916170 T AT 94916170T AT E211762 T1 ATE211762 T1 AT E211762T1
- Authority
- AT
- Austria
- Prior art keywords
- beta1
- tgf
- growth factor
- transforming growth
- treating
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93107089 | 1993-04-30 | ||
| EP93107849 | 1993-05-13 | ||
| PCT/EP1994/001362 WO1994025588A2 (en) | 1993-04-30 | 1994-04-29 | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE211762T1 true ATE211762T1 (de) | 2002-01-15 |
Family
ID=26133181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94916170T ATE211762T1 (de) | 1993-04-30 | 1994-04-29 | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
| AT99125278T ATE235549T1 (de) | 1993-04-30 | 1994-04-29 | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99125278T ATE235549T1 (de) | 1993-04-30 | 1994-04-29 | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6455689B1 (de) |
| JP (2) | JP3555952B2 (de) |
| AT (2) | ATE211762T1 (de) |
| AU (1) | AU6794594A (de) |
| DE (2) | DE69429617T2 (de) |
| WO (1) | WO1994025588A2 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| US6884787B2 (en) | 2001-07-14 | 2005-04-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of transforming growth factor-beta 3 expression |
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| US6207816B1 (en) * | 1995-06-02 | 2001-03-27 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to growth factors |
| DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
| EP0856579A1 (de) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden |
| WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| CA2334960C (en) | 1998-06-10 | 2012-01-03 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| US6436909B1 (en) * | 1999-09-17 | 2002-08-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of transforming growth factor-β expression |
| EP1133988A1 (de) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens |
| US7101543B2 (en) | 2000-03-31 | 2006-09-05 | Novarx | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| PT1456380E (pt) * | 2001-11-02 | 2012-07-23 | Giuliani Int Ltd | Inibidores smad7 para o tratamento de doenças do snc |
| KR20030056538A (ko) * | 2001-12-28 | 2003-07-04 | 주식회사 웰진 | 리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발 |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US20050090433A1 (en) * | 2002-11-18 | 2005-04-28 | Vicuron Pharmaceuticals, Inc | Dalbavancin compositions for treatment of bacterial infections |
| CN1756773A (zh) * | 2003-03-03 | 2006-04-05 | 斯蒂潘公司 | 降低天然橡胶胶乳制品的变应原性蛋白质含量的方法 |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| US7750142B2 (en) * | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| ATE466595T1 (de) * | 2003-07-16 | 2010-05-15 | Rvx Therapeutics Inc | Verbindungen und methoden für das downregulating der effekte von tgf-beta |
| ES2594734T3 (es) * | 2003-12-19 | 2016-12-22 | Autotelic Llc | Terapia de combinación que asocia un antagonista de TGF-beta con un agente quimioterapéutico |
| EP2248895B8 (de) | 2003-12-19 | 2016-09-21 | Autotelic LLC | Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert |
| EP1708712A1 (de) * | 2003-12-24 | 2006-10-11 | Scios, Inc. | Behandlung von malignen gliomen mit tgf-beta-hemmern |
| AU2005218759B2 (en) * | 2004-02-27 | 2009-07-16 | Antisense Pharma Gmbh | Pharmaceutical composition |
| EP1568383A3 (de) * | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| DE102004025881A1 (de) * | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonukleotide zur Beeinflussung des Haarwachstums |
| NZ562954A (en) * | 2005-05-05 | 2009-10-30 | Antisense Pharma Gmbh | Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors |
| ES2369328T3 (es) * | 2005-09-19 | 2011-11-29 | Isis Pharmaceuticals, Inc. | Modulación de la expresión del receptor de glucagón. |
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| EP1998810A4 (de) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Erhöhung der endothelialen thromboresistenz |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| US8822425B2 (en) * | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
| EP2524038A4 (de) * | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | Modulation der transformierung einer wachstumsfaktor-beta-1-expression |
| US8911736B2 (en) | 2010-03-12 | 2014-12-16 | Genzyme Corporation | Combination therapy for treating breast cancer |
| WO2011154542A1 (en) | 2010-06-11 | 2011-12-15 | Artisense Pharma Gmbh | Method for selective oligonucleotide modification |
| KR20130131414A (ko) | 2010-12-27 | 2013-12-03 | 엘에스아이피 환도 운에이고우도우가이샤 | ｉＰＳ 세포와 그 제조법 |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| CA2849273C (en) | 2011-09-20 | 2020-07-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
| CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| ES2917222T3 (es) | 2011-12-28 | 2022-07-07 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| BR112015024729B1 (pt) | 2013-03-27 | 2022-02-15 | Isarna Therapeutics Gmbh | Oligonucleotídeo antissenso, seu uso e composição farmacêutica |
| JP6492053B2 (ja) | 2013-03-27 | 2019-03-27 | イサルナ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾ｔｇｆ−ベータオリゴヌクレオチド |
| DK2978846T3 (da) | 2013-03-27 | 2020-04-06 | Isarna Therapeutics Gmbh | Modificeret tgf-beta-oligonukleotid til anvendelse i en fremgangsmåde til forebyggelse og/eller behandling af en oftalmisk sygdom |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| WO2016187312A1 (en) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| KR20220039639A (ko) | 2020-09-21 | 2022-03-29 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| AU2024284737A1 (en) * | 2023-06-05 | 2026-01-22 | Gmp Biotechnology Limited | Tgfb2-irf5 therapeutics for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0293785A3 (de) * | 1987-05-29 | 1990-05-02 | Oncogen Limited Partnership | Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1 |
| US5221620A (en) * | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5525468A (en) * | 1992-05-14 | 1996-06-11 | Ribozyme Pharmaceuticals, Inc. | Assay for Ribozyme target site |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| US5464945A (en) * | 1992-08-28 | 1995-11-07 | Hoffmann-La Roche Inc. | Oligonucleotide probes specific for the human alpha satellite locus |
-
1994
- 1994-04-29 AT AT94916170T patent/ATE211762T1/de active
- 1994-04-29 DE DE69429617T patent/DE69429617T2/de not_active Expired - Lifetime
- 1994-04-29 AU AU67945/94A patent/AU6794594A/en not_active Abandoned
- 1994-04-29 DE DE69432375T patent/DE69432375T2/de not_active Expired - Lifetime
- 1994-04-29 JP JP52389894A patent/JP3555952B2/ja not_active Expired - Lifetime
- 1994-04-29 WO PCT/EP1994/001362 patent/WO1994025588A2/en not_active Ceased
- 1994-04-29 AT AT99125278T patent/ATE235549T1/de active
- 1994-04-29 US US08/535,249 patent/US6455689B1/en not_active Expired - Lifetime
-
2002
- 2002-05-16 US US10/146,058 patent/US20030040499A1/en not_active Abandoned
-
2003
- 2003-06-30 JP JP2003188524A patent/JP3600831B2/ja not_active Expired - Lifetime
-
2006
- 2006-12-29 US US11/647,586 patent/US7667027B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08509370A (ja) | 1996-10-08 |
| DE69432375T2 (de) | 2004-02-12 |
| WO1994025588A2 (en) | 1994-11-10 |
| JP3555952B2 (ja) | 2004-08-18 |
| DE69429617D1 (de) | 2002-02-14 |
| US7667027B2 (en) | 2010-02-23 |
| JP2004024264A (ja) | 2004-01-29 |
| WO1994025588A3 (en) | 1994-12-22 |
| ATE235549T1 (de) | 2003-04-15 |
| DE69432375D1 (de) | 2003-04-30 |
| AU6794594A (en) | 1994-11-21 |
| DE69429617T2 (de) | 2002-08-22 |
| US20030040499A1 (en) | 2003-02-27 |
| US20080214483A1 (en) | 2008-09-04 |
| JP3600831B2 (ja) | 2004-12-15 |
| US6455689B1 (en) | 2002-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE211762T1 (de) | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) | |
| EP1762619A3 (de) | Multi-tumor abweichende wachstumsgene | |
| FI951612A0 (fi) | Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia | |
| CA2048450A1 (en) | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria | |
| CA2200371A1 (en) | Human npik gene | |
| NO983716D0 (no) | Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon | |
| EP0702694A4 (de) | $i(PSEUDOMONAS SYRINGAE) pv. $i(SYRINGAE hrpY)-GEN | |
| WO1996038473A3 (en) | Antimicrobial cationic peptides | |
| EP1008649A3 (de) | Antisense Oligonukleotide zur Behandlung von Immunosuppressive Wirkungen von TGF-beta2 | |
| CY1106978T1 (el) | Ενζυμα φωσφοδιεστερασης | |
| ZA931333B (en) | Recombinant plant enzyme. | |
| DK2256205T3 (da) | Porphorymonas gingivalis-polypeptider og -polynukleotider | |
| DE68926455D1 (de) | Verfahren zur identifizierung von bakterien | |
| ATE387493T1 (de) | Gene, die für proteine mit transglykolysierungsaktivität kodieren. | |
| PL317046A1 (en) | Endotransglycosidase to tomato xyloglucane | |
| DE69934415D1 (de) | Neuartiges collectin | |
| AU6144294A (en) | Plant virus resistance conferring polyribozyme and resistant plants producing same | |
| DE59812837D1 (de) | Orotidin-5'-phosphatdecarboxylase-gen, genkonstrukt enthaltend dieses gen und seine verwendung | |
| DE59611131D1 (de) | Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung | |
| IT1255666B (it) | Sequenze nucleotidiche codificanti per una dna polimerasi. | |
| ES2109373T3 (es) | Nueva proteina inhibidora de trombina a partir de garrapatas. | |
| CA2203801A1 (en) | Nucleotide sequences mediating male fertility and method of using same | |
| TH52857A (th) | แบคทีเรียของสกุล Bacillus และโปรตีนสำหรับฆ่าแมลง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |